Compare Direxion Daily Semiconductor Bear 3X Shares (SOXS) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily Semiconductor Bear 3X Shares vs BIO-TECHNE Corp — how do they compare? Direxion Daily Semiconductor Bear 3X Shares trades at $31.92 (market cap $1.89B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: BIO-TECHNE Corp is far larger — about 6× Direxion Daily Semiconductor Bear 3X Shares's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Direxion Daily Semiconductor Bear 3X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily Semiconductor Bear 3X Shares for 11 Days and BIO-TECHNE Corp for 63 Days on average.
| SOXS | TECH | |
|---|---|---|
Market Cap | $1.89B | $11.37B |
Volume | 66,118,733 | 3,153,511 |
Sector | Leveraged / Inverse | Health |
52-Week High | $988.00 | $72.61 |
52-Week Low | $29.62 | $43.31 |
Typical Hold Time | 11 Days | 63 Days |
Enterprise Value | — | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SOXS, the Direxion Daily Semiconductor Bear 3X ETF, trades at $30.645, up 3.43% today, reflecting its inverse leveraged exposure to semiconductor stocks. The technical outlook is bearish, with moving averages signaling strong selling pressure, while oscillators are neutral. Recent news highlights the fund's volatility and tactical use during semiconductor sector weakness, as seen in July 2026 when it surged on chip stock declines. A 1:10 stock split occurred on July 15, 2026, adjusting share structure.
The outlook for SOXS remains highly speculative, suited only for short-term traders betting against semiconductors. Key risks include the fund's decay from daily rebalancing, reliance on sector volatility, and persistent AI demand supporting chip stocks. Investors should avoid long-term holdings due to structural erosion and elevated loss potential in rising markets.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Direxion Daily Semiconductor Bear 3X Shares
SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
